AstraZeneca, MedImmune, Lilly join U-M to discover new CKD treatments

AstraZeneca and its global biologics research and development arm MedImmune have entered into collaboration with the University of Michigan and Eli Lilly to discover new therapeutic targets to treat chronic kidney diseases (CKD).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news